CANC
ABBV icon

Culbertson A N & Co’s AbbVie ABBV Stock Holding History

Culbertson A N & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.5M Buy
80,406
+13,269
+20% +$2.94M 2.27% 10
2025
Q4 		$15.3M Sell
67,137
-649
-1% -$148K 2.1% 12
2025
Q3 		$15.7M Sell
67,786
-570
-0.8% -$116K 2.22% 11
2025
Q2 		$12.7M Sell
68,356
-2,058
-3% -$382K 1.95% 10
2025
Q1 		$14.8M Sell
70,414
-304
-0.4% -$59.1K 2.36% 6
2024
Q4 		$12.6M Sell
70,718
-82
-0.1% -$15.1K 2% 10
2024
Q3 		$14M Sell
70,800
-54
-0.1% -$10.1K 2.25% 7
2024
Q2 		$12.2M Sell
70,854
-1,426
-2% -$236K 2.12% 10
2024
Q1 		$13.2M Sell
72,280
-1,456
-2% -$251K 2.27% 7
2023
Q4 		$11.4M Sell
73,736
-999
-1% -$146K 2.13% 8
2023
Q3 		$11.1M Sell
74,735
-696
-0.9% -$102K 2.24% 8
2023
Q2 		$10.2M Sell
75,431
-1,186
-2% -$174K 1.96% 11
2023
Q1 		$12.2M Sell
76,617
-1,397
-2% -$214K 2.49% 6
2022
Q4 		$12.6M Sell
78,014
-982
-1% -$151K 2.66% 5
2022
Q3 		$10.6M Sell
78,996
-2,612
-3% -$375K 2.46% 7
2022
Q2 		$12.5M Sell
81,608
-550
-0.7% -$84K 2.71% 5
2022
Q1 		$13.3M Buy
82,158
+1,310
+2% +$190K 2.51% 6
2021
Q4 		$10.9M Sell
80,848
-1,035
-1% -$122K 2.06% 9
2021
Q3 		$8.83M Buy
81,883
+1,447
+2% +$165K 1.81% 12
2021
Q2 		$9.06M Buy
80,436
+692
+0.9% +$77.9K 1.89% 12
2021
Q1 		$8.63M Buy
79,744
+1,542
+2% +$165K 1.9% 12
2020
Q4 		$8.38M Sell
78,202
-467
-0.6% -$44.9K 1.99% 10
2020
Q3 		$6.89M Sell
78,669
-5,646
-7% -$532K 1.82% 13
2020
Q2 		$8.28M Buy
84,315
+1,080
+1% +$95.1K 2.27% 11
2020
Q1 		$6.34M Buy
83,235
+256
+0.3% +$21.8K 2.05% 12
2019
Q4 		$7.35M Sell
82,979
-1,671
-2% -$139K 1.89% 13
2019
Q3 		$6.41M Buy
84,650
+813
+1% +$55.7K 1.75% 15
2019
Q2 		$6.1M Buy
83,837
+433
+0.5% +$34K 1.69% 18
2019
Q1 		$6.72M Buy
83,404
+235
+0.3% +$19.2K 1.94% 14
2018
Q4 		$7.67M Sell
83,169
-2,033
-2% -$179K 2.44% 9
2018
Q3 		$8.06M Buy
85,202
+1,010
+1% +$95.8K 2.2% 13
2018
Q2 		$7.8M Sell
84,192
-60
-0.1% -$5.86K 2.32% 10
2018
Q1 		$7.97M Sell
84,252
-2,618
-3% -$288K 2.39% 10
2017
Q4 		$8.4M Buy
86,870
+273
+0.3% +$25.7K 2.37% 10
2017
Q3 		$7.7M Buy
86,597
+507
+0.6% +$38.6K 2.35% 11
2017
Q2 		$6.24M Buy
86,090
+697
+0.8% +$46.9K 1.98% 18
2017
Q1 		$5.56M Sell
85,393
-595
-0.7% -$37.4K 1.81% 21
2016
Q4 		$5.38M Sell
85,988
-244
-0.3% -$14.9K 1.83% 22
2016
Q3 		$5.44M Buy
86,232
+1,255
+1% +$81.2K 1.93% 20
2016
Q2 		$5.26M Buy
84,977
+2,460
+3% +$150K 1.95% 22
2016
Q1 		$4.71M Buy
82,517
+317
+0.4% +$17.7K 1.83% 24
2015
Q4 		$4.87M Buy
82,200
+3,210
+4% +$185K 1.93% 22
2015
Q3 		$4.3M Buy
78,990
+2,859
+4% +$186K 1.81% 22
2015
Q2 		$5.12M Buy
76,131
+1,980
+3% +$129K 1.99% 17
2015
Q1 		$4.34M Buy
74,151
+2,732
+4% +$165K 1.73% 23
2014
Q4 		$4.67M Buy
71,419
+5,209
+8% +$328K 1.93% 21
2014
Q3 		$3.82M Buy
66,210
+1,532
+2% +$85.1K 1.65% 26
2014
Q2 		$3.65M Buy
64,678
+545
+0.8% +$28.6K 1.59% 26
2014
Q1 		$3.3M Buy
64,133
+1,427
+2% +$72.1K 1.54% 27
2013
Q4 		$3.31M Buy
62,706
+920
+1% +$45.2K 1.61% 26
2013
Q3 		$2.76M Buy
61,786
+1,555
+3% +$68.9K 1.48% 30
2013
Q2 		$2.49M Buy
+60,231
New +$2.63M 1.4% 31

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Culbertson A N & Co's ABBV Position: Q1 2026 in Review

Culbertson A N & Co increased its AbbVie (ABBV) stake by 20% in Q1 2026, buying an estimated $2.94M and bringing the position to 80,406 shares worth $17.5M. The position accounts for 2.27% of the portfolio, ranked #10.

Culbertson A N & Co first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Culbertson A N & Co held 80,406 shares of AbbVie worth $17.5M as of Q1 2026.
  • Culbertson A N & Co bought 13,269 AbbVie shares in Q1 2026, an estimated $2.94M.
  • AbbVie made up 2.27% of Culbertson A N & Co's portfolio in Q1 2026, its #10 holding.
  • Culbertson A N & Co first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Culbertson A N & Co's 13F filing for Q1 2026, filed 12 May 2026.